Mario Negri Institute for Pharmacological Research
marionegri.itTotal trials
155
Active
44
Phase 3
24
Total enrollment
1,647,768
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 13 of 13 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Olaparib | — | — | — | — | 2 | ||
| Bevacizumab | — | — | — | — | — | 1 | |
| Acetyl-l-carnitine | — | — | — | — | — | 1 | |
| Patiromer 8400 MG [Veltassa] | — | — | — | — | — | 1 | |
| Obinutuzumab | — | — | — | — | — | 2 | |
| Durvalumab | — | — | — | — | — | 3 | |
| Noble gas Argon | — | — | — | — | — | 1 | |
| Ceralasertib | — | — | — | — | — | 1 | |
| Abemaciclib | — | — | — | — | — | 1 | |
| Multi-omics Analysis | — | — | — | — | — | 1 | |
| RATG | — | — | — | — | — | 1 | |
| Basiliximab | — | — | — | — | — | 1 | |
| Octreotide | — | — | — | — | — | 1 |
Next readouts
- 2024-12-31
- 2025-09
- 2026-02
- 2026-03-31
- 2026-07
- 2027-03-15
- 2027-04
- 2028-06
- 2029-03
- 2029-03
Top conditions
- Membranous Nephropathy6
- Type 2 Diabetes5
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)5
- COVID-194
- Atypical Hemolytic Uremic Syndrome4
- Hypertension4
- Kidney Transplant4
- Emergency Departments4
Frequently asked questions about Mario Negri Institute for Pharmacological Research
- How many clinical trials does Mario Negri Institute for Pharmacological Research have on ClinicalTrials.gov?
- Mario Negri Institute for Pharmacological Research is listed as the lead sponsor on 155 clinical trials in ClinicalTrials.gov, 44 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Mario Negri Institute for Pharmacological Research's trials are in Phase 3?
- 24 of Mario Negri Institute for Pharmacological Research's trials are in Phase 3, spread across 13 active drug programs.
- What therapeutic areas does Mario Negri Institute for Pharmacological Research focus on?
- Mario Negri Institute for Pharmacological Research's most-studied conditions on ClinicalTrials.gov are Membranous Nephropathy, Type 2 Diabetes, Autosomal Dominant Polycystic Kidney Disease (ADPKD), COVID-19, Atypical Hemolytic Uremic Syndrome.
- When are Mario Negri Institute for Pharmacological Research's next clinical trial readouts?
- Mario Negri Institute for Pharmacological Research has 10 upcoming primary-completion readouts tracked here; the soonest is “Outcome of ADPKD With Octreotide LAR”, expected around 2024-12-31.